Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus platinum-taxane chemotherapy in locally recurrent head and neck squamous cell carcinoma by TP53 and PIK3CA status
ChiCTR2100046731Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- May 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab, cisplatin, carboplatin and paclitaxel in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Overall survival. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100046731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046731.